Erlotinib Recruiting Phase 2 Trials for Familial Adenomatous Polyposis (FAP) / APC Gene Mutation / Attenuated Familial Adenomatous Polyposis Prevention

IndicationsStatusPurposePhase
RecruitingPrevention2
clinicaltrials.gov IdentifierTitleDrugs
NCT02961374Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer